Effect of short-term and long-term treatments with σ ligands on the N -methyl-d -aspartate response in the CA3 region of the rat dorsal hippocampus
Open Access
- 1 March 1997
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 120 (7) , 1351-1359
- https://doi.org/10.1038/sj.bjp.0701042
Abstract
Long‐term treatments with the σ ligand haloperidol decrease the density of σ receptors in mammalian CNS. We have shown that σ ligands, such as di(2‐tolyl)guanidin (DTG), potentiate dose‐dependently, with bell‐shaped dose‐response curves, the neuronal response of pyramidal neurones to N‐methyl‐d‐aspartate (NMDA) in the CA3 region of the rat dorsal hippocampus. σ Ligands producing such a potentiation were denoted ‘agonists’. This potentiation was suppressed by low doses of other σ ligands denoted ‘antagonists’. High doses of DTG and JO‐1784 did not modify the NMDA response but acted as ‘antagonists’ by suppressing the potentiation induced by σ ‘agonists’. Following a 21‐day treatment with haloperidol as well as with high doses of DTG or JO‐1784, after a 48 h washout, the acute administration of σ ‘agonists’ failed to induce any potentiation of the NMDA response. Following a 21 day treatment with a low dose of DTG or JO‐1784, after a 48 h washout, the neuronal response to microiontophoretic applications of NMDA was markedly increased. A 21 day treatment with low or high doses of (+)‐pentazocine, after a 48 h washout, did not produce any change. Following a two day treatment with a high dose of haloperidol, DTG, JO‐1784 and (+)‐pentazocine, after a 24 h washout, the potentiation of the NMDA response induced by the acute administration of the σ ‘agonists’ was unchanged. With the minipumps on board, with DTG and JO‐1784, a dose‐dependent enhancement of the NMDA response was seen but no effect was observed in the groups of rats treated at the same doses with haloperidol or (+)‐pentazocine. The present data suggest that long‐term treatments with σ ‘antagonists’ induce a desensitization of the σ receptors, whereas long‐term treatments with σ ‘agonists’ induce a supersensitivity of the σ receptors. British Journal of Pharmacology (1997) 120, 1351–1359; doi:10.1038/sj.bjp.0701042Keywords
This publication has 34 references indexed in Scilit:
- Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptorsPsychopharmacology, 1997
- The effects of sigma ligands and of neuropeptide Y on N-methyl-d-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxinBritish Journal of Pharmacology, 1994
- Haloperidol treatment differentially regulates [3H]DTG and [3H](+)-3-PPP labeled σ binding sitesEuropean Journal of Pharmacology, 1993
- Modification of the N-methyl-D-aspartate response by antidepressant σ receptor ligandsEuropean Journal of Pharmacology, 1993
- An open study of remoxipride in the long-term treatment of schizophrenia-Journal of Psychopharmacology, 1992
- JO 1784, a potent and selective ligand for rat and mouse brain σ-sitesJournal of Pharmacy and Pharmacology, 1990
- Regulation of σ‐Receptors: High‐ and Low‐Affinity Agonist States, GTP Shifts, and Up‐Regulation by Rimcazole and 1,3‐Di(2‐Tolyl)guanidineJournal of Neurochemistry, 1989
- Evidence for a multi-site model of the rat brain σ receptorEuropean Journal of Pharmacology, 1989
- Receptor mechanisms in antipsychotic drug action: focus on sigma receptorsThe Journal of Neuropsychiatry and Clinical Neurosciences, 1989
- Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol.Circulation Research, 1988